Rationale: Mucoepidermoid carcinoma (MEC) of the breast is a rare entity, with an estimated incidence of only 0.2% to 0.3% of all primary breast tumors. The radiological features of breast MEC have scarcely been investigated mainly because of its rarity. In this article, we present a case of breast MEC diagnosed at our hospital and review the literature, focusing on radiological findings and radiologic–pathologic correlations that could improve clinical management of this entity. To the best of our knowledge, our study is the first review of the literature that focuses on the radiological features of breast MEC. Patient concerns: A 47-year-old premenopausal woman presented with a painless palpable mass in the right breast. Diagnosis: Mammography and ultrasonography revealed a mass with suspicious malignant features, which was categorized as Breast Imaging Reporting and Data System category 4c. A 14-gauge core-needle biopsy revealed an intermediate-grade MEC of the breast. The patient underwent breast magnetic resonance imaging and chest computed tomography for preoperative evaluation. Postoperative histopathological examination confirmed a diagnosis of intermediate-grade MEC. The clinical staging was T2N0M0. Interventions: The patient underwent breast-conserving surgery, adjuvant chemotherapy, radiotherapy, and hormonal therapy. Outcomes: No evidence of recurrence has been reported over 37 months. Lessons: The imaging characteristics of breast MEC were variable, and there were no specific radiological features for diagnosis. The presence of cystic components on radiological imaging is likely to be an indicator of a low-grade tumor and better prognosis, although the number of reported cases is limited.

Background and Objectives: The extracellular volume fraction (fECV) of the liver, as measured by contrast-enhanced computed tomography (CT), has been shown to correlate closely with the histological stages of hepatic fibrosis. This study aimed to investigate the diagnostic performance of a liver extracellular volume fraction derived from dual-energy CT (DECT) for evaluating liver functional reserve based on the Child–Pugh class in cirrhotic patients, compared with other noninvasive markers. Materials and Methods: This retrospective study included 258 patients with liver cirrhosis who underwent contrast-enhanced DECT. The fECV was measured using iodine maps derived from equilibrium phase images obtained 3 min after contrast injection at 100/140 Sn kVp. Statistical analyses included Welch’s ANOVA with post hoc tests, Spearman’s correlation, and ROC analysis. The area under the curve (AUC) was compared among fECV and other noninvasive markers (aspartate transaminase to platelet ratio index [APRI], Fibrosis-4 [FIB-4], and model for end-stage liver disease [MELD]) using DeLong’s test. Intra- and interobserver reliability of fECV was assessed with the intraclass correlation coefficient (ICC). The area under the receiver operating characteristic curve (AUC) for differentiating Child–Pugh classes was compared among the fECV and other noninvasive markers (aspartate transaminase to platelet ratio index [APRI], Fibrosis-4 [FIB-4], and model for end-stage liver disease [MELD]). Results: The fECV increased significantly with advancing Child–Pugh classes (p < 0.001), showing a moderate correlation with Child–Pugh class (r = 0.53). The mean differences in fECV among the Child–Pugh classes were 8.88 between A and B (95% confidence interval [CI], 5.85–11.92; p < 0.001) and 7.42 between B and C (95% CI, 1.92–12.91: p < 0.001). The AUC for differentiating Child–Pugh classes A and B demonstrated no significant differences among the fECV (0.84), APRI (0.83, p > 0.99) and FIB-4 (0.83, p > 0.99), except for MELD, which had a significantly higher AUC (0.94, p = 0.047). For differentiating Child-Pugh classes B and C, the fECV demonstrated a significantly higher AUC (0.78), compared with FIB-4 (0.50, p = 0.038) and APRI (0.49, p = 0.037), whereas no significant difference was observed between fECV and MELD (0.92, p = 0.12). The intra- and interobserver reliabilities of the fECV measurements were excellent (ICC, 0.93; 95% CI, 0.91–0.95 and 0.91; 95% CI, 0.88–0.92, respectively). Conclusions: DECT derived fECV is a useful noninvasive marker for assessing liver functional reserve based on the Child–Pugh classification.

Cervical cancer is a leading cause of cancer-related mortality in women, with poor prognosis when diagnosed at advanced stages. Bevacizumab, an anti-vascular endothelial growth factor agent, has shown promising results in the treatment of metastatic cervical cancer. The combination of bevacizumab with paclitaxel and cisplatin (TP) as first-line chemotherapy is associated with improved survival rates in patients with metastatic cervical cancer. In this study, we aimed to evaluate the effectiveness and safety of first-line chemotherapy with bevacizumab and TP in patients with advanced cervical cancer in South Korea and investigate the clinical value of posttreatment plasma levels of squamous cell carcinoma antigen (SCC Ag) as an independent prognostic factor for survival. This retrospective study included 33 patients with metastatic cervical cancer who received bevacizumab and TP as first-line chemotherapy between January 2016 and December 2022 at the Gyeongsang National University Hospital. First-line therapy with bevacizumab and TP significantly improved progression-free and overall survival (OS) [26.3 (95% confidence interval (CI), 18.3–34.3) and 39.9 (95% CI, 23.8–56) months, respectively]. Patients who achieved normalization of posttreatment SCC Ag levels had significantly longer OS compared to those who did not [69.1 (95% CI, 17.6–120.6) vs 18.4 (95% CI, 10.9–25.9) months, respectively (hazard ratio 12.4; P < .001)]. The treatment regimen was well-tolerated, with most patients reporting manageable side effects. First-line chemotherapy with bevacizumab and TP demonstrated efficacy and tolerability in Korean patients with metastatic cervical cancer. Additionally, normalization of posttreatment SCC antigen levels serves as a potential prognostic marker for patients undergoing this type of chemotherapy.